Cell therapy for inherited retinal disease (CLARICO)
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This study tests a new cell therapy (OpCT-001) for adults with inherited retinal diseases that affect the light-sensing cells. It aims to see if the treatment is safe and possibly helps improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of a primary photoreceptor disease (a type of inherited eye condition that affects the light-sensing cells in your retina).
- Your vision in the study eye must fall within a specific range: for Phase 1, between counting fingers and 20/40; for Phase 2, between 20/25 and 20/60 on an eye chart.
- Your retina must have areas that are suitable for the study treatment to be injected.
- You cannot have active eye inflammation, infection, glaucoma, diabetic eye disease, or significant macular edema.
- You cannot have had any prior cell therapy, gene therapy, retinal implant, or organ transplant.
- You must not have had eye surgery in the last 3 months or have a current or recent (within 5 years) cancer (except treated basal cell skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This study tests a new gene therapy for people with advanced rod-cone dystrophy, a genetic condition that causes progressive vision loss. The treatment is given as an injection into the eye, and the study aims to see if it is safe and if it can help improve or preserve vision.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This trial tests a one-time gene therapy given under the retina to treat a rare inherited eye disease that causes poor vision. It may help slow down vision loss or improve sight.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.